Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $5.63 in the last session, up 4.07% from day before closing price of $5.41. In other words, the price has increased by $4.07 from its previous closing price. On the day, 14.45 million shares were traded. RXRX stock price reached its highest trading level at $5.7 during the session, while it also had its lowest trading level at $5.46.
Ratios:
We take a closer look at RXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.81 and its Current Ratio is at 3.81. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 27 ’25 when Gibson Christopher sold 138,574 shares for $6.04 per share. The transaction valued at 836,987 led to the insider holds 1,117,450 shares of the business.
Gibson Christopher bought 138,574 shares of RXRX for $836,987 on Mar 27 ’25. On Mar 05 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $6.58 each. As a result, the insider received 131,600 and left with 1,256,024 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2224255488 and an Enterprise Value of 1777349504. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.46 while its Price-to-Book (P/B) ratio in mrq is 2.16. Its current Enterprise Value per Revenue stands at 30.207 whereas that against EBITDA is -4.017.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.90, which has changed by -0.290932 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -15.38%, while the 200-Day Moving Average is calculated to be -18.41%.
Shares Statistics:
According to the various share statistics, RXRX traded on average about 25.72M shares per day over the past 3-months and 28501730 shares per day over the past 10 days. A total of 389.55M shares are outstanding, with a floating share count of 305.89M. Insiders hold about 23.91% of the company’s shares, while institutions hold 60.29% stake in the company. Shares short for RXRX as of 1743379200 were 88501554 with a Short Ratio of 3.44, compared to 1740700800 on 80716710. Therefore, it implies a Short% of Shares Outstanding of 88501554 and a Short% of Float of 23.94.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
